Reply to: “Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?”

Shira Zelber-Sagi, Yochai Schonmann, Hanny Yeshua, Itay Bentov

Research output: Contribution to journalLetterpeer-review

Original languageAmerican English
Pages (from-to)385-386
Number of pages2
JournalDigestive and Liver Disease
Volume53
Issue number3
DOIs
StatePublished - Mar 2021

Keywords

  • Cardiovascular
  • Fibrosis marker
  • NAFLD
  • Primary care
  • Primary prevention

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Hepatology

Cite this